The TKm30 NOG mouse is a next-generation TK-based NOG model designed for inducible liver injury and subsequent human hepatocyte engraftment. Developed to address key limitations of the legacy TK-NOG strain, TKm30 NOG supports TK transgene expression in both males and females, restores male fertility, and enables homozygous breeding. These improvements simplify colony management, increase cohort usability, and provide a more scalable platform for TK-based humanized liver model workflows.
TKm30 NOG
Application Areas:
| Model No. | Nomenclature | Genotype |
|---|---|---|
| 23534-F | NOD.Cg-Tg(Ttr-UL23*)4-9 Prkdcscid Il2rgtm1SugJic/JicTac | tg/tg;sp/sp;ko/ko |
| 23534-M | NOD.Cg-Tg(Ttr-UL23*)4-9 Prkdcscid Il2rgtm1SugJic/JicTac | tg/tg;sp/sp;ko/y |
View:
Select One
- Description
- Related Products & Services
- Data
- Price & Licensing
- Health Report
- Overview
- Genetics
- Applications & Therapeutic Areas
- Transit, Housing & Welfare
- Diet
Overview
Nomenclature: NOD.Cg-Tg(Ttr-UL23*)4-9 Prkdcscid Il2rgtm1SugJic/JicTac
Model Description
The TKm30 NOG mouse carries a modified HSV-thymidine kinase (TK) transgene that enables selective ablation of murine hepatocytes following ganciclovir administration. After liver injury induction, mice can be engrafted with human hepatocytes to generate humanized liver models for translational research applications.
Compared with the original TK-NOG model, TKm30 NOG is designed to reduce sex-related limitations in model use and improve breeding efficiency. These refinements support more consistent animal utilization and a more practical production strategy for TK-based liver humanization studies.
Key Features and Advantages
Compared with the original TK-NOG model, TKm30 NOG offers:
- Inducible liver injury for hepatocyte engraftment: TK-based ablation of murine hepatocytes following ganciclovir administration supports downstream generation of humanized liver models.
- Improved cohort usability: TK transgene expression in both male and female mice enables broader use of study animals compared with legacy TK-NOG.
- Simplified colony management: Restored male fertility and homozygous breeding eliminate routine PCR genotyping and reduce production of unusable animals.
- Scalable production strategy: A continuous-production colony supports improved availability and broader access to TK-based liver humanization workflows.
Together, these improvements position TKm30 NOG as the intended successor to TK-NOG within Taconic’s NOG portfolio.
Availability
- Offering: Live, naïve (unengrafted) TKm30 NOG mice
- Sex: Male and female
- Production status: Continuous production colony established
- Succession: Intended replacement for TK‑NOG
Recommended Controls
The recommended control strain for TKm30 NOG studies is the CIEA NOG mouse, depending on study design.
Licensing & Use
Special licensing terms may apply. Please refer to the Price & Licensing section or contact Taconic for details.
Origin
The NOG mouse was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The NOG mouse was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The HSVtk transgene was generated by CIEA via microinjection into NOD/Shi inbred mice. The transgenic construct contains the mouse albumin enhancer/promoter (mAlb En/Pro), the chimeric intron, HSVtk cDNA, and the 3'-UTR of the human growth hormone gene with a polyadenylation signal (hGH pA). There was a single site of transgene integration, and HSVtk mRNA was selectively expressed in the liver. The TK-NOD/Shi mice were backcrossed onto the NOG mouse at CIEA and imported into Taconic in 2014.
Genetics
Applications & Therapeutic Areas
- Cardiometabolic
- General Use
- Immunology
- Infectious Disease
- Oncology and Immuno-Oncology
- Hepatitis A, B, C
- HIV and AIDS
- MASLD
The TKm30 NOG mouse is intended for use in studies requiring controlled liver injury and subsequent hepatocyte replacement, including:
- Humanized liver model development
- In vivo drug metabolism and pharmacokinetics (DMPK)
- Liver toxicity and safety assessment
- Drug-drug interaction studies
- Infectious disease research involving hepatotropic pathogens
- Oncology and immunology studies requiring a humanized liver component
- Metabolic-associated steatohepatitis (MASH) studies requiring a humanized liver component
Engraftment outcomes depend on study design, hepatocyte source, and experimental conditions.
Transit, Housing & Welfare
Need more info? Click the live chat button or Contact Us
Packing Practices
Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns. When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.
Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age." Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.
Taconic discourages other types of custom packing requests as they can have a negative impact on animal welfare. Learn more.
Diet
- Services
Data
Sex-dependent sensitivity to GVCV-mediated liver ablation in TKM30 NOG mice
Figure 1. Sex-dependent responses to VGCV-mediated liver injury in TKm30 NOG mice: Body weight and liver injury responses following administration of 25 mg/kg valine-ganciclovir (VGCV; used for improved water solubility) demonstrate clear sex-dependent differences. At baseline, female mice had lower body weights than males. Following treatment, females exhibited greater body weight loss, with some animals reaching humane endpoint criteria by Day 7, while males remained below endpoint thresholds. Consistent with this increased sensitivity, females showed markedly elevated serum ALT levels, with multiple animals exceeding 1000 U/L, indicating more severe hepatocellular injury compared to males. Importantly, these findings do not indicate that females are unsuitable for use. Rather, they highlight the need for sex-specific dose optimization to achieve controlled liver injury. Together, these data demonstrate that conditioning regimens should be tailored by sex when designing hepatocyte engraftment studies in TKm30 NOG mice.
- Licensing
- Pricing - USD
- Pricing - EUR
- Pricing - DKK
- Pricing - USD Nonprofit
- Pricing - EUR Nonprofit
- Pricing - DKK Nonprofit
- Select my Health Standard
Licensing
Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions.
For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.
The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
- Japanese Patent No. 3,753,321
- US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
EP Patent No. 1,338,198 - Japanese Trademark Reg. No. 4,823,423
- US Trademark Reg. No. 3,118,040
- EU Trademark Reg. No. 3,736,758
Pricing - USD
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | US$650.00 |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | US$650.00 |
Pricing - EUR
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | 565,00 € |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | 565,00 € |
Pricing - DKK
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | kr.4.849,00 |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | kr.4.849,00 |
Pricing - USD Nonprofit
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | US$500.00 |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | US$500.00 |
Pricing - EUR Nonprofit
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | 435,00 € |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | 435,00 € |
Pricing - DKK Nonprofit
Opportunist Free (OF) Health Standard
23534 Female
23534-F Genotype tg/tg;ko/ko;ko/wt
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | kr.3.730,00 |
23534 Male
23534-M Genotype tg/tg;ko/ko;ko/y
| Age in Weeks | Quantity 1 - 999 |
|---|---|
| 3 to 10 | kr.3.730,00 |
Select my Health Standard
Need help choosing the right Taconic Biosciences health standard for your research?
Use the Health Standard Selector to enter your exclusion list. The tool will tell you which health standards meet your requirements.
View the production locations(s) and the accompanying current IHMS™ Health Report and Taconic Health Standard for this model
Schedule A Scientific Consultation
Connect directly with a member of our Scientific Solutions team who can help you select the most appropriate model and maximize your experimental success.
Related Models
Featured Resources
Schedule A Scientific Consultation
Speak with a scientist who can help you select the most appropriate model and maximize your experimental success.